Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling

Oncogene

Volumn 31, Issue 25, 2012, Pages 3086-3097

  Liao, Y C ^a   Ruan, J W ^a   Lua, I ^a   Li, M H ^b   Chen, W L ^c   Wang, J R Y ^b   Kao, R H ^b   Chen, J H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

cytoskeleton regulation; GEF H1; hPTTG1; RhoA; tumour metastasis

Indexed keywords

F ACTIN; PAXILLIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN H1; SECURIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INVASION; CANCER RISK; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CYTOSKELETON; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

BREAST NEOPLASMS; CARCINOMA; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84862655609     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.476     Document Type: Article

References (46)

1. Bernal J, Luna R, Espina A, La?zaro I, Ramos-Morales F, Romero F et al. (2002). Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306-311.
2. Birkenfeld J, Nalbant P, Yoon S, Bokoch G. (2008). Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell Biol 18: 210-219.
3. Birukova AA, Adyshev D, Gorshkov B, Bokoch GM, Birukov KG, Verin AD. (2006). GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 290: L540-L548.
4. Chambers AF, Groom AC, MacDonald IC. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
5. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY et al. (2010). Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 12: 457-467.
6. Chang Y, Nalbant P, Birkenfeld J, Chang Z, Bokoch G. (2008). GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA. Mol Biol Cell 19: 2147-2153.
7. Chesnokova V, Melmed S. (2010). Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol 326: 55-59.
8. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S et al. (2008). p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105: 17498-17503.
9. Chien W, Pei L. (2000). A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem 275: 19422-19427.
10. Clevenger CV. (2004). Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460.
11. del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C et al. (1997). Rho proteins induce metastatic properties in vivo. Oncogene 15: 3047-3057.
12. Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M et al. (1998). hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17: 2187-2193.
13. Fidler IJ. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
14. Funabiki H, Kumada K, Yanagida M. (1996). Fission yeast Cut1 and Cut2 are essential for sister chromatid separation, concentrate along the metaphase spindle and form large complexes. EMBO J 15: 6617-6628.
15. Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. (2006). Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol 26: 4017-4027.
16. Gupta GP, Massague J. (2006). Cancer metastasis: building a framework. Cell 127: 679-695.
17. Hall A. (1998). Rho GTPases and the actin cytoskeleton. Science 279: 509-514.
18. Heaney A, Singson R, McCabe C, Nelson V, Nakashima M, Melmed S. (2000). Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716-719.
19. Hornig NC, Knowles PP, McDonald NQ, Uhlmann F. (2002). The dual mechanism of separase regulation by securin. Curr Biol 12: 973-982.
20. Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y et al. (2008). Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res 68: 3214-3224.
21. Jaffe AB, Hall A. (2005). Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21: 247-269.
22. Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A et al. (2007). Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 28: 749-759.
23. Krendel M, Zenke F, Bokoch G. (2002). Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 4: 294-301.
24. Libermann TA, Zerbini LF. (2006). Targeting transcription factors for cancer gene therapy. Curr Gene Ther 6: 17-33.
25. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH. (2008). Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28: 7096-7108.
26. Mizuarai S, Yamanaka K, Kotani H. (2006). Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 66: 6319-6326.
27. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP. (2005). Securin is overexpressed in breast cancer. Mod Pathol 18: 985-990.
28. Pei L. (2001). Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276: 8484-8491.
29. Pei L, Melmed S. (1997). Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433-441.
30. Ramaswamy S, Ross K, Lander E, Golub T. (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
31. Ren Y, Li R, Zheng Y, Busch H. (1998). Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases. J Biol Chem 273: 34954-34960.
32. Ridley AJ. (2001). Rho GTPases and cell migration. J Cell Sci 114: 2713-2722.
33. Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-Toro JA et al. (2001). Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 29: 1300-1307.
34. Sahai E, Marshall CJ. (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
35. Schaller MD. (2001). Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472.
36. Schmitz AA, Govek EE, Bottner B, Van Aelst L. (2000). Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261: 1-12.
37. Smith VE, Franklyn JA, McCabe CJ. (2010). Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev Mol Med 12: e38.
38. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. (2004). PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13: 80-81.
39. Tong Y, Eigler T. (2009). Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol 43: 179-185.
40. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC et al. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.
41. Vlotides G, Eigler T, Melmed S. (2007). Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165-186.
42. Wang Z, Melmed S. (2000). Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275: 7459-7461.
43. Wennerberg K, Der CJ. (2004). Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci 117: 1301-1312.
44. Wittmann T, Waterman-Storer CM. (2001). Cell motility: can Rho GTPases and microtubules point the way? J Cell Sci 114: 3795-3803.
45. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD et al. (1999). Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156-166.
46. Zou H, McGarry TJ, Bernal T, Kirschner MW. (1999). Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418-422.